Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19320
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLevin, V. A.en
dc.contributor.authorMaor, M. H.en
dc.contributor.authorThall, P. F.en
dc.contributor.authorYung, W. K.en
dc.contributor.authorBruner, J.en
dc.contributor.authorSawaya, R.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorLeeds, N.en
dc.contributor.authorWoo, S.en
dc.contributor.authorRodriguez, L.en
dc.contributor.authoret al.,en
dc.date.accessioned2015-11-24T18:58:53Z-
dc.date.available2015-11-24T18:58:53Z-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19320-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBrain Neoplasms/*drug therapy/*radiotherapy/surgeryen
dc.subjectCarboplatin/*therapeutic useen
dc.subjectChemotherapy, Adjuvanten
dc.subjectCombined Modality Therapyen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Administration Scheduleen
dc.subjectGlioblastoma/*drug therapy/*radiotherapy/surgeryen
dc.subjectHumansen
dc.subjectLomustine/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectProcarbazine/administration & dosageen
dc.subjectSurvival Analysisen
dc.subjectVincristine/administration & dosageen
dc.titlePhase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiformeen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/7673023-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1995-
heal.abstractPURPOSE: To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors. METHODS AND MATERIALS: Between 1988 and 1992, 83 patients received 1.9-2.0 Gy radiation three times a day with 2-h infusions of 33 mg/m2 carboplatin for two 5-day cycles separated by 2 weeks; following radiotherapy, patients received procarbazine, lomustine (CCNU), and vincristine (PCV) for 1 year or until tumor progressed. RESULTS: Eighty-three patients were evaluable for analysis. Seventy-four of the 83 patients (89%) received one or more courses of PCV; their median survival was 55 weeks. Total resection was performed in 20% (15 of 74), subtotal resection in 69% (51 of 74), and biopsy in 11% (8 of 74); reoperation (total or subtotal resection) was performed in 28 patients (37%). Survival was worst for those > or = 61 year old (median 35 weeks). Fits of the Cox proportional hazards regression model showed covariates individually predictive of improved survival were younger age (p < 0.01), smaller log of radiation volume (p = 0.008), total or subtotal resection vs. biopsy (p = 0.056), and higher Karnofsky performance status (p = 0.055). A multivariate analysis showed that age (p = 0.013) and extent of initial surgery (p = 0.003) together were predictive of a better survival with no other variables providing additional significance. Only 8.4% (7 of 83) of patients had clinically documented therapy-associated neurotoxicity ("radiation necrosis"). CONCLUSION: When comparable selection criteria were applied, the survival in this study is similar to the results currently attainable with other chemoradiation approaches. The relative safety of accelerated fractionated radiotherapy, as used in this study with carboplatin, enables concomitant full-dose administration of chemotherapy or radiosensitizing agents in glioblastoma multiforme patients.en
heal.journalNameInt J Radiat Oncol Biol Physen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons